Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Thalmann

Showing results (271-280 of 307) with videos related to

Pageof 31
Sort By:
European Urology|January 6, 2026
Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: Long-term Data from the SAKK 09/10 Randomised Phase 3 TrialPirus Ghadjar, Stefanie Hayoz, Daniel R Zwahlen, et al.
The Journal of Pathology|April 1, 2018
CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinomaSofia Karkampouna, Danny van der Helm, Peter C Gray, et al.
The Lancet. Oncology|March 29, 2012
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trialNicholas D James, Matthew R Sydes, Malcolm D Mason, et al.
European Urology|June 18, 2021
Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 TrialPirus Ghadjar, Stefanie Hayoz, Jürg Bernhard, et al.
Cancers|January 11, 2024
Lymphovascular Invasion at the Time of Radical Prostatectomy Adversely Impacts Oncological OutcomesNiranjan J Sathianathen, Marc A Furrer, Clancy J Mulholland, et al.
Urologic Oncology|October 23, 2017
The prognostic effect of salvage surgery and radiotherapy in patients with recurrent primary urethral carcinomaGeorgios Gakis, Tina Schubert, Todd M Morgan, et al.
Molecular Oncology|September 8, 2020
Cationic amphiphilic drugs as potential anticancer therapy for bladder cancerGeertje van der Horst, Arjanneke F van de Merbel, Eline Ruigrok, et al.
European Urology Oncology|January 11, 2022
A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14Cyrill A Rentsch, George N Thalmann, Ilaria Lucca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 31, 2022
Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09/10 randomized clinical trialA Dal Pra, P Ghadjar, S Hayoz, et al.
European Urology|March 21, 2025
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 GuidelinesAntoine G van der Heijden, Harman Max Bruins, Albert Carrion, et al.
Pageof 31

Showing results (271-280 of 307) with videos related to

Sort By:
Pageof 31
European Urology|January 6, 2026
Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: Long-term Data from the SAKK 09/10 Randomised Phase 3 TrialPirus Ghadjar, Stefanie Hayoz, Daniel R Zwahlen, et al.
The Journal of Pathology|April 1, 2018
CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinomaSofia Karkampouna, Danny van der Helm, Peter C Gray, et al.
The Lancet. Oncology|March 29, 2012
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trialNicholas D James, Matthew R Sydes, Malcolm D Mason, et al.
European Urology|June 18, 2021
Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 TrialPirus Ghadjar, Stefanie Hayoz, Jürg Bernhard, et al.
Cancers|January 11, 2024
Lymphovascular Invasion at the Time of Radical Prostatectomy Adversely Impacts Oncological OutcomesNiranjan J Sathianathen, Marc A Furrer, Clancy J Mulholland, et al.
Urologic Oncology|October 23, 2017
The prognostic effect of salvage surgery and radiotherapy in patients with recurrent primary urethral carcinomaGeorgios Gakis, Tina Schubert, Todd M Morgan, et al.
Molecular Oncology|September 8, 2020
Cationic amphiphilic drugs as potential anticancer therapy for bladder cancerGeertje van der Horst, Arjanneke F van de Merbel, Eline Ruigrok, et al.
European Urology Oncology|January 11, 2022
A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14Cyrill A Rentsch, George N Thalmann, Ilaria Lucca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 31, 2022
Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09/10 randomized clinical trialA Dal Pra, P Ghadjar, S Hayoz, et al.
European Urology|March 21, 2025
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 GuidelinesAntoine G van der Heijden, Harman Max Bruins, Albert Carrion, et al.
Pageof 31